Drug intelligence / Profile preview

bupivacaine hydrochloride + paracetamol + orphenadrine

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intravenous, Intramuscular, Rectal, Epidural, Intrathecal, Infiltration, Perineural

Overview

This appears to be a combination of three active ingredients: bupivacaine hydrochloride (a local anesthetic), paracetamol (an analgesic), and orphenadrine (a muscle relaxant). While combinations of paracetamol and orphenadrine exist for treating painful musculoskeletal conditions, and bupivacaine is used for local/regional anesthesia, there is no evidence in the provided information of all three being combined in a single formulation.

Targets

NaV (Voltage-gated sodium channels)HRH1 (Histamine H1 Receptor)PTGER1 (Prostaglandin E Receptor 1)COXNMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on bupivacaine hydrochloride + paracetamol + orphenadrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bupivacaine hydrochloride + paracetamol + orphenadrine.

Explore the full profile